Doxazosin Cor 1 A Pharma

Doxazosin Cor 1 A Pharma is an oral medication that contains the active ingredient Doxazosin Mesilate. It is supplied as a prescription tablet marketed in the European Union. Doxazosin belongs to the selective alpha‑1 adrenergic receptor antagonist class and is used to manage high blood pressure and symptoms of benign prostatic hyperplasia. It relaxes blood vessels and prostate smooth muscle, lowering resistance and easing urine flow.

Doxazosin Cor 1 A Pharma is indicated for two primary therapeutic areas.

- Hypertension (essential high blood pressure) – used as monotherapy or in combination to achieve target blood pressure. - Benign prostatic hyperplasia (BPH) – alleviates urinary obstruction symptoms such as hesitancy, weak stream, and nocturia. - Adjunctive treatment of renal artery stenosis‑related hypertension. - Off‑label use in certain cases of pheochromocytoma under specialist supervision.

Side‑effect profiles of Doxazosin Cor 1 A Pharma reflect its vasodilatory and smooth‑muscle‑relaxing actions.

Common: - Dizziness or light‑headedness, especially when standing quickly. - Headache. - Fatigue or mild weakness. - Nasal congestion. - Peripheral edema. - Postural (orthostatic) hypotension.

Serious: - Severe hypotension or syncope. - Tachycardia or arrhythmia. - Angioedema (swelling of face, lips, tongue). - Hepatic dysfunction (elevated liver enzymes). - Priapism (prolonged painful erection).

Before prescribing Doxazosin Cor 1 A Pharma, clinicians should evaluate several safety considerations.

- History of orthostatic hypotension or volume depletion. - Severe hepatic impairment. - Concomitant use of other antihypertensives may increase risk of low blood pressure. - Known hypersensitivity to doxazosin or related quinazoline compounds. - Elderly patients may have an increased risk of falls due to blood‑pressure lowering effects. - Pregnancy and lactation status are unknown; use only if the potential benefit justifies the risk.

Doxazosin can interact with other medicines that affect blood pressure or hepatic metabolism.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Other alpha‑blockers or potent vasodilators (e.g., prazosin, nitroglycerin).

Use with caution: - Diuretics, especially loop or thiazide types. - ACE inhibitors or angiotensin‑II receptor blockers. - Sildenafil and other PDE5 inhibitors. - Beta‑blockers. - Medications that may cause electrolyte disturbances.